Resources for Clinicians
Resources for Healthcare Professionals
Cure JM January 2025 – Virtual Summit
In January, the Cure JM Clinical Care Network was pleased to invite juvenile dermatomyositis healthcare professionals to join us virtually for the latest presentations from world-leading researchers and clinicians on advancements in basic research, translational studies, and best-practice clinical care in juvenile dermatomyositis.
Cure JM September 2024 – Virtual Summit
We are pleased to invite all juvenile dermatomyositis healthcare professionals to join us virtually for the latest presentations, sharing clinical best practices to help providers diagnose, treat, and care for juvenile myositis patients.
The Potential of JAKs in Fighting JM
In our June 2024 “Ask the Doc” Town Hall, Dr. Julie Paik joins in a Q&A session to shed light on what JAK inhibitors are, how they work in JM, when parents might consider discussing JAKs as a treatment option, and the pros and cons of their use.
Understanding Second-Line Treatments and Side Effects
Second-line treatments refer to options beyond steroids and methotrexate. They are designed to manage JM while reducing reliance on those medications. We understand that adding new treatments to your child’s regimen can be intimidating. However, rest assured that your doctor has carefully considered the benefits and risks of each option to design the best treatment plan for your family.
Optimizing Myositis Care: The Role of Biologics
Biologics are a therapies that derived from living cells or through biological processes. They are a promising new class of drugs used to treat myositis.
Skin Disease for Clinicians
Dr. Victoria Werth, M.D., discusses the identification and treatment of skin manifestations associated with dermatomyositis. Her talk covers diagnostic criteria, various skin manifestations, the latest treatment approaches, and the complexities of managing this condition, all aimed at improving patient outcomes and quality of life.
Treatment Plans for Juvenile Myositis
A treatment plan is based on many factors, including the severity and expression of the juvenile dermatomyositis (JDM). Each case is different and the symptoms can change over time.
Cure JM May 2024 – Virtual Symposium
The Cure JM Clinical Care Network hosted our second quarterly virtual symposium of 2024, “Juvenile Dermatomyositis – Advances in Clinical Care, Basic Research, and Translational Studies.” World-leading researchers and clinicians presented sessions on various topics, with the primary goal of enhancing the overall patient and provider experience through collaboration and best practice sharing.
Research Volunteers and Assistance Needed
Help researchers find the cause and a cure for juvenile myositis by volunteering for these important studies.
Pioneering JM Care – Integrating Research With a Multidisciplinary Approach to Care
Dr. Jessica Turnier of the University of Michigan / Mott’s Children’s Hospital is dedicated to creating new directions for JM research and wider perspectives on how it is treated. About the University of Michigan, she states, “When I came to Michigan, there were a lot of myositis patients, and I just developed a really strong connection with those patients.”
Join Cure JM
Sign up and you will receive the quarterly Cure JM newsletter for clinicians and physicians.
